Research & Literature

Glomerular Density in Biopsy-Proven Hypertensive Nephrosclerosis.

Haruhara K, Tsuboi N, Kanzaki G, et al.

American journal of hypertension 2015; (28(9)):1164-71 doi:10.1093/ajh/hpu267.

Biomarkers in chronic kidney disease, from kidney function to kidney damage.

Lopez-Giacoman S, Madero M

World journal of nephrology 2015; (4(1)):57-73 doi:10.5527/wjn.v4.i1.57.

Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review.

Levey AS, Becker C, Inker LA

JAMA 2015; (313(8)):837-46 doi:10.1001/jama.2015.0602.

[Hypertensive urgency and emergency].

Henny-Fullin K, Buess D, Handschin A, et al.

Therapeutische Umschau. Revue therapeutique 2015; (72(6)):405-11 doi:10.1024/0040-5930/a000693.

[Hypertensive emergencies and urgencies].

Phan DG, Dreyfuss-Tubiana C, Blacher J

Presse medicale (Paris, France : 1983) 2015; (44(7-8)):737-44.

Important causes of chronic kidney disease in South Africa.

Moosa MR, Van der Walt I, Naicker S, Meyers AM

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 2015; (105(4)):2681 doi:10.7196/samj.9535.

Interdisciplinary care clinics in chronic kidney disease.

Johns TS, Yee J, Smith-Jules T, et al.

BMC nephrology 2015; (16()):161 doi:10.1186/s12882-015-0158-6.

Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis.

Tangri N, Grams ME, Levey AS, et al.

JAMA 2016; (315(2)):164-74 doi:10.1001/jama.2015.18202.

Effect of Proteinuria and Glomerular Filtration Rate on Renal Outcome in Patients with Biopsy-Proven Benign Nephrosclerosis.

Sumida K, Hoshino J, Ueno T, et al.

PloS one 2016; (11(1)):e0147690 doi:10.1371/journal.pone.0147690.

Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.

Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, et al.

PLoS medicine 2016; (13(3)):e1001971 doi:10.1371/journal.pmed.1001971.

Malignant Hypertension Revisited-Does This Still Exist?

Shantsila A, Lip GYH

American journal of hypertension 2017; (30(6)):543-549 doi:10.1093/ajh/hpx008.

APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis.

Cooper A, Ilboudo H, Alibu VP, et al.

eLife 2017; (6()).

Community Pharmacist Training-and-Communication Network and Drug-Related Problems in Patients With CKD: A Multicenter, Cluster-Randomized, Controlled Trial.

Lalonde L, Quintana-Bárcena P, Lord A, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2017; (70(3)):386-396 doi:10.1053/j.ajkd.2017.05.008.

Geographic Variation and US County Characteristics Associated With Rapid Kidney Function Decline.

Bowe B, Xie Y, Xian H, et al.

Kidney international reports 2017; (2(1)):5-17 doi:10.1016/j.ekir.2016.08.016.

Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT).

Rocco MV, Sink KM, Lovato LC, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2018; (71(3)):352-361 doi:10.1053/j.ajkd.2017.08.021.

Chronic kidney disease care models in low- and middle-income countries: a systematic review.

Stanifer JW, Von Isenburg M, Chertow GM, Anand S

BMJ global health 2018; (3(2)):e000728 doi:10.1136/bmjgh-2018-000728.

Clinicopathological predictors for progression of chronic kidney disease in nephrosclerosis: a biopsy-based cohort study.

Yamanouchi M, Hoshino J, Ubara Y, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2019; (34(7)):1182-1188 doi:10.1093/ndt/gfy121.

[New calcium channel blockers for the treatment of hypertension].

Tamargo J

Hipertension y riesgo vascular 2017; (34 Suppl 2()):5-8 doi:10.1016/S1889-1837(18)30067-9.

Biological Variability of Estimated GFR and Albuminuria in CKD.

Waikar SS, Rebholz CM, Zheng Z, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2018; (72(4)):538-546 doi:10.1053/j.ajkd.2018.04.023.

Donor's APOL1 Risk Genotype and "Second Hits" Associated With De Novo Collapsing Glomerulopathy in Deceased Donor Kidney Transplant Recipients: A Report of 5 Cases.

Chang JH, Husain SA, Santoriello D, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2019; (73(1)):134-139 doi:10.1053/j.ajkd.2018.05.008.

Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease.

Scheppach JB, Raff U, Toncar S, et al.

Hypertension (Dallas, Tex. : 1979) 2018; (72(4)):929-936 doi:10.1161/HYPERTENSIONAHA.118.11608.

African American Living Donors' Attitudes About APOL1 Genetic Testing: A Mixed Methods Study.

Gordon EJ, Amόrtegui D, Blancas I, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2018; (72(6)):819-833 doi:10.1053/j.ajkd.2018.07.017.

Cardiovascular and Renal Outcomes in an Excellent Chronic Kidney Disease Clinic Compared with an Outpatient Clinic in a Primary Care Setting: A Retrospective Cohort Study.

Aiumtrakul N, Euswas K, Phichedwanichskul K, et al.

Kidney diseases (Basel, Switzerland) 2019; (5(3)):144-152 doi:10.1159/000495464.

Practical Considerations for APOL1 Genotyping in the Living Kidney Donor Evaluation.

Mena-Gutierrez AM, Reeves-Daniel AM, Jay CL, Freedman BI

Transplantation 2020; (104(1)):27-32 doi:10.1097/TP.0000000000002933.

Hypertensive crisis: clinical characteristics of patients with hypertensive urgency, emergency and pseudocrisis at a public emergency department.

Pierin AMG, Flórido CF, Santos JD

Einstein (Sao Paulo, Brazil) 2019; (17(4)):eAO4685 doi:10.31744/einstein_journal/2019AO4685.

ACE inhibitors and ARBs: Managing potassium and renal function.

Momoniat T, Ilyas D, Bhandari S

Cleveland Clinic journal of medicine 2019; (86(9)):601-607 doi:10.3949/ccjm.86a.18024.

APOL1-Associated Collapsing Focal Segmental Glomerulosclerosis in a Patient With Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset in Infancy (SAVI).

Abid Q, Best Rocha A, Larsen CP, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2020; (75(2)):287-290 doi:10.1053/j.ajkd.2019.07.010.

APOL1 and Kidney Disease: From Genetics to Biology.

Friedman DJ, Pollak MR

Annual review of physiology 2020; (82()):323-342 doi:10.1146/annurev-physiol-021119-034345.

Hypertensive kidney disease: a true epidemic or rare disease?

Stompór T, Perkowska-Ptasińska A

Polish archives of internal medicine 2020; (130(2)):130-139 doi:10.20452/pamw.15150.

Clinical Phenotypes and Long-term Prognosis in White Patients With Biopsy-Verified Hypertensive Nephrosclerosis.

Øvrehus MA, Oldereid TS, Dadfar A, et al.

Kidney international reports 2020; (5(3)):339-347 doi:10.1016/j.ekir.2019.12.010.

Time-averaged proteinuria during follow-up and renal prognosis in patients with biopsy-proven benign nephrosclerosis.

Amano H, Koike K, Haruhara K, et al.

Clinical and experimental nephrology 2020; (24(8)):688-695 doi:10.1007/s10157-020-01885-w.

Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes.

Nichols GA, Déruaz-Luyet A, Brodovicz KG, et al.

BMC nephrology 2020; (21(1)):167 doi:10.1186/s12882-020-01792-y.

Hypertensive emergencies and urgencies in emergency departments: a systematic review and meta-analysis.

Astarita A, Covella M, Vallelonga F, et al.

Journal of hypertension 2020; (38(7)):1203-1210 doi:10.1097/HJH.0000000000002372.

Hypertensive nephrosclerosis: wider kidney biopsy indications may be needed to improve diagnostics.

Hallan SI, Øvrehus MA, Bjørneklett R, et al.

Journal of internal medicine 2021; (289(1)):69-83 doi:10.1111/joim.13146.

The prevalence of chronic kidney disease in Iceland according to KDIGO criteria and age-adapted estimated glomerular filtration rate thresholds.

Jonsson AJ, Lund SH, Eriksen BO, et al.

Kidney international 2020; (98(5)):1286-1295 doi:10.1016/j.kint.2020.06.017.

Hypertensive nephropathy: a major roadblock hindering the advance of precision nephrology.

Carriazo S, Vanessa Perez-Gomez M, Ortiz A

Clinical kidney journal 2020; (13(4)):504-509 doi:10.1093/ckj/sfaa162.

Development, Reliability, and Validity of the Home Blood Pressure Monitoring Adherence Scale for Patients with Chronic Kidney Disease.

Wang Y, Li K, Li H, et al.

Patient preference and adherence 2020; (14()):1863-1872 doi:10.2147/PPA.S264287.

Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use Among Hypertensive US Adults With Albuminuria.

Chu CD, Powe NR, McCulloch CE, et al.

Hypertension (Dallas, Tex. : 1979) 2021; (77(1)):94-102 doi:10.1161/HYPERTENSIONAHA.120.16281.

Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.

Cheung AK, Chang TI, Cushman WC, et al.

Kidney international 2021; (99(3)):559-569 doi:10.1016/j.kint.2020.10.026.

Potential implications of the 2021 KDIGO blood pressure guideline for adults with chronic kidney disease in the United States.

Foti KE, Wang D, Chang AR, et al.

Kidney international 2021; (99(3)):686-695 doi:10.1016/j.kint.2020.12.019.

Diagnosis, Education, and Care of Patients with APOL1-Associated Nephropathy: A Delphi Consensus and Systematic Review.

Freedman BI, Burke W, Divers J, et al.

Journal of the American Society of Nephrology : JASN 2021; (32(7)):1765-1778 doi:10.1681/ASN.2020101399.

Management of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice Guideline.

Tomson CRV, Cheung AK, Mann JFE, et al.

Annals of internal medicine 2021; (174(9)):1270-1281 doi:10.7326/M21-0834.

Altered dietary salt intake for people with chronic kidney disease.

McMahon EJ, Campbell KL, Bauer JD, et al.

The Cochrane database of systematic reviews 2021; (6()):CD010070 doi:10.1002/14651858.CD010070.pub3.

Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease.

McCarthy GM, Blasio A, Donovan OG, et al.

Disease models & mechanisms 2021; (14(8)) doi:10.1242/dmm.048952.

Home Blood Pressure Monitoring: Current Status and New Developments.

Kario K

American journal of hypertension 2021; (34(8)):783-794 doi:10.1093/ajh/hpab017.

A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives.

Evans M, Lewis RD, Morgan AR, et al.

Advances in therapy 2022; (39(1)):33-43 doi:10.1007/s12325-021-01927-z.

Emerging Insights Into Chronic Renal Disease Pathogenesis in Hypertension From Human and Animal Genomic Studies.

Dhande IS, Braun MC, Doris PA

Hypertension (Dallas, Tex. : 1979) 2021; (78(6)):1689-1700 doi:10.1161/HYPERTENSIONAHA.121.18112.

Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations.

Shubrook JH, Neumiller JJ, Wright E

Postgraduate medicine 2022; (134(4)):376-387 doi:10.1080/00325481.2021.2009726.

Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70.

Costantino VV, Gil Lorenzo AF, Bocanegra V, Vallés PG

Cells 2021; (10(11)) doi:10.3390/cells10113146.

APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study.

Young BA, Wilson JG, Reiner A, et al.

Kidney medicine 2021; (3(6)):962-973.e1 doi:10.1016/j.xkme.2021.05.004.

KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD.

Drawz PE, Beddhu S, Bignall ONR, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2022; (79(3)):311-327 doi:10.1053/j.ajkd.2021.09.013.

APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program.

Hung AM, Shah SC, Bick AG, et al.

JAMA internal medicine 2022; (182(4)):386-395 doi:10.1001/jamainternmed.2021.8538.

Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.

Neuen BL, Oshima M, Agarwal R, et al.

Circulation 2022; (145(19)):1460-1470 doi:10.1161/CIRCULATIONAHA.121.057736.

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.

Yau K, Dharia A, Alrowiyti I, Cherney DZI

Kidney international reports 2022; (7(7)):1463-1476 doi:10.1016/j.ekir.2022.04.094.

Mesangial Injury and Capillary Ballooning Precede Podocyte Damage in Nephrosclerosis.

Kriz W, Wiech T, Gröne HJ

The American journal of pathology 2022; (192(12)):1670-1682 doi:10.1016/j.ajpath.2022.08.007.

Submaximal Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dosing Among Persons With Proteinuria.

Chu CD, Powe NR, Estrella MM, et al.

Mayo Clinic proceedings 2022; (97(11)):2099-2106 doi:10.1016/j.mayocp.2022.07.010.

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.

,

Lancet (London, England) 2022; (400(10365)):1788-1801 doi:10.1016/S0140-6736(22)02074-8.

Prevalence of neurological complaints among emergency department patients with severe hypertension.

Liberman AL, Kamel H, Lappin R, et al.

The American journal of emergency medicine 2023; (64()):90-95 doi:10.1016/j.ajem.2022.11.033.

GPR97 deficiency ameliorates renal interstitial fibrosis in mouse hypertensive nephropathy.

Wu JC, Wang XJ, Zhu JH, et al.

Acta pharmacologica Sinica 2023; (44(6)):1206-1216 doi:10.1038/s41401-022-01041-y.

Effectiveness of thiazide and thiazide-like diuretics in advanced chronic kidney disease: a systematic review and meta-analysis.

Teles F, Peçanha de Miranda Coelho JA, Albino RM, et al.

Renal failure 2023; (45(1)):2163903 doi:10.1080/0886022X.2022.2163903.

Physical activity and nutrition in chronic kidney disease.

Wang AY, March DS, Burton JO

Current opinion in clinical nutrition and metabolic care 2023; (26(4)):385-392 doi:10.1097/MCO.0000000000000947.

Clinical Outcomes in Hypertensive Emergency: A Systematic Review and Meta-Analysis.

Siddiqi TJ, Usman MS, Rashid AM, et al.

Journal of the American Heart Association 2023; (12(14)):e029355 doi:10.1161/JAHA.122.029355.

EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors.

Fernández-Fernandez B, Sarafidis P, Soler MJ, Ortiz A

Clinical kidney journal 2023; (16(8)):1187-1198 doi:10.1093/ckj/sfad082.

Early diagnosis of chronic kidney disease in patients with diabetes in France: multidisciplinary expert opinion, prevention value and practical recommendations.

Hannedouche T, Rossignol P, Darmon P, et al.

Postgraduate medicine 2023; (135(7)):633-645 doi:10.1080/00325481.2023.2256208.

Genetic Inhibition of APOL1 Pore-Forming Function Prevents APOL1-Mediated Kidney Disease.

Hung AM, Assimon VA, Chen HC, et al.

Journal of the American Society of Nephrology : JASN 2023; (34(11)):1889-1899 doi:10.1681/ASN.0000000000000219.

[Are thiazide diuretics ineffective with a glomerular filtration rate lower than 50 ml/min?]

Hausberg M

Innere Medizin (Heidelberg, Germany) 2024; (65(2)):180-184 doi:10.1007/s00108-023-01617-8.

Roles of the mechanosensitive ion channel Piezo1 in the renal podocyte injury of experimental hypertensive nephropathy.

Ogino S, Yoshikawa K, Nagase T, et al.

Hypertension research : official journal of the Japanese Society of Hypertension 2024; (47(3)):747-759 doi:10.1038/s41440-023-01536-z.

Evaluating ApoL1 Genetic Testing Policy Options for Transplant Centers: A Delphi Consensus Panel Project with Stakeholders.

McIntosh T, Walsh H, Baldwin K, et al.

Clinical journal of the American Society of Nephrology : CJASN 2024; (19(4)):494-502 doi:10.2215/CJN.0000000000000397.

Clinical impact of the Kidney Failure Risk Equation for vascular access planning.

Hahn Lundström U, Ramspek CL, Dekker FW, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2024; (39(12)):2079-2087 doi:10.1093/ndt/gfae064.

Single-pill combination for treatment of hypertension: Just a matter of practicality or is there a real clinical benefit?

Coca A, Whelton SP, Camafort M, et al.

European journal of internal medicine 2024; (126()):16-25 doi:10.1016/j.ejim.2024.04.011.

Clinical Effects of Yoga and Meditational Practices on the Holistic Health of Chronic Kidney Disease Patients: A Systematic Review.

Gautam S, Kiran UV

Cureus 2024; (16(4)):e57546 doi:10.7759/cureus.57546.

The Management of Elevated Blood Pressure in the Acute Care Setting: A Scientific Statement From the American Heart Association.

Bress AP, Anderson TS, Flack JM, et al.

Hypertension (Dallas, Tex. : 1979) 2024; (81(8)):e94-e106 doi:10.1161/HYP.0000000000000238.

Comparison of routine office blood pressure measurement versus standardized attended manually activated oscillometric office blood pressure measurement in patients with chronic kidney disease.

Chellappan A, Kansal K

Journal of family medicine and primary care 2024; (13(5)):1894-1903 doi:10.4103/jfmpc.jfmpc_1619_23.

Clinical Outcomes in Patients with CKD and Rapid or Non-rapid eGFR Decline: A Report from the DISCOVER CKD Retrospective Cohort.

Heerspink H, Nolan S, Carrero JJ, et al.

Advances in therapy 2024; (41(8)):3264-3277 doi:10.1007/s12325-024-02913-x.

Design and Rationale of the Phase 2 Baricitinib Study in Apolipoprotein L1-Mediated Kidney Disease (JUSTICE).

Olabisi OA, Barrett NJ, Lucas A, et al.

Kidney international reports 2024; (9(9)):2677-2684 doi:10.1016/j.ekir.2024.06.033.

Baseline characteristics of the first 302 patients included for acute malignant hypertension crisis in the prospective multidisciplinary HAMA cohort.

Boulestreau R, Lorthioir A, Dreau H, et al.

Journal of hypertension 2024; (42(12)):2131-2138 doi:10.1097/HJH.0000000000003851.

Heterogeneous afferent arteriolopathy: a key concept for understanding blood pressure-dependent renal damage.

Kohagura K, Zamami R, Oshiro N, et al.

Hypertension research : official journal of the Japanese Society of Hypertension 2024; (47(12)):3383-3396 doi:10.1038/s41440-024-01916-z.

Vascular injury in glomerulopathies: the role of the endothelium.

Barbosa GSB, Câmara NOS, Ledesma FL, et al.

Frontiers in nephrology 2024; (4()):1396588 doi:10.3389/fneph.2024.1396588.

The Diagnostic Yield of Genomic Sequencing-based Genetic Kidney Disease Testing in Kidney Transplant Candidates: Experience at an Urban US Transplant Center.

Abu Al Rub F, Elsurer Afsar R, Fleetwood VA, et al.

Transplantation 2025; (109(7)):1201-1208 doi:10.1097/TP.0000000000005288.

Effect of Antihypertensive Drugs on Rapid Decline in Estimated Glomerular Filtration Rate in Japanese Patients With Chronic Kidney Disease.

Fujimoto K, Kikuchi M, Nakai M, et al.

American journal of hypertension 2025; (38(7)):476-484 doi:10.1093/ajh/hpaf041.

Optimizing renin-angiotensin-aldosterone inhibition in advanced chronic kidney disease: balancing benefits and risks.

Spencer S, Bhandari S

Current opinion in nephrology and hypertension 2025; (34(6)):469-476 doi:10.1097/MNH.0000000000001076.

Genetic Testing in Adults over 50 Years with Chronic Kidney Disease: Diagnostic Yield and Clinical Implications in a Specialized Kidney Genetics Clinic.

Schott C, Alajmi M, Bukhari M, et al.

Genes 2025; (16(4)) doi:10.3390/genes16040408.

APOL1 testing in clinical practice and opportunities for new therapies.

Lee T, Ma L, Freedman BI

Current opinion in nephrology and hypertension 2025; (34(6)):500-506 doi:10.1097/MNH.0000000000001082.

APOL1 kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Ojo AO, Adu D, Bramham K, et al.

Kidney international 2025; (108(5)):763-779 doi:10.1016/j.kint.2025.05.017.

Risk-based referral model to nephrologist specialist care in Stockholm.

Caldinelli A, Faucon AL, Sjölander A, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2025; (41(1)):102-111 doi:10.1093/ndt/gfaf128.

A primary care guide to the screening and pharmacologic management of chronic kidney disease in people living with type 2 diabetes.

Wright EE, Cebrian A, Ngui D

Primary care diabetes 2025; (19(5)):411-421 doi:10.1016/j.pcd.2025.05.005.

Renal Histology Findings in Malignant Hypertension, a Systematic Review.

Maisons V, Demir F, Fillon A, et al.

Hypertension (Dallas, Tex. : 1979) 2026; (83(1)):177-188 doi:10.1161/HYPERTENSIONAHA.125.25069.

Evaluation of Kidney Failure Risk Equation score for vascular access planning in an Australian cohort.

Hong R, Hirsch D, Li K, et al.

Internal medicine journal 2026; (56(3)):364-372 doi:10.1111/imj.70281.

Heterogeneity of Estimated GFR Slopes According to Etiology, Estimated GFR and Urinary Albumin-to-Creatinine Ratio in a Large Cohort of Patients With CKD.

Behning C, Schultheiss UT, Nadal J, et al.

Kidney international reports 2026; (11(2)):103696 doi:10.1016/j.ekir.2025.11.021.

Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.

Agarwal R, Correa-Rotter R, Navaneethan SD, et al.

Journal of the American Society of Nephrology : JASN 2026; doi:10.1681/ASN.0000001071.

Clinical Utility of Standardized Genetic Testing in Kidney Transplant Candidate Evaluation.

Caliskan Y, Elsurer Afsar R, Abu Al Rub F, et al.

Transplantation direct 2026; (12(5)):e1933 doi:10.1097/TXD.0000000000001933.

Acute Estimated Glomerular Filtration Rate Decline After Initiation of Therapies That Slow Kidney Disease Progression: Clinical Practice Implications.

Cherney DZI, Alicic RZ, Bonaca MP

Mayo Clinic proceedings 2026; (101(8)):1347-1366 doi:10.1016/j.mayocp.2026.01.010.

The Role of Non-Coding RNA in the Pathogenesis of Hypertensive Nephropathy.

Plewa P, Figiel K, Ćmil M, et al.

Cells 2026; (15(8)) doi:10.3390/cells15080701.

Non-Proteinuric Diabetic Kidney Disease: A Comprehensive Review.

Natarajan P, Shaik F, Chatterjee A, Prabhakar SS

Life (Basel, Switzerland) 2026; (16(4)) doi:10.3390/life16040533.

Dynamic Bayesian networks to predict loss of kidney function: a cross-institution use case in a large cohort with or at-risk of CKD.

Petousis P, Gordon D, Duru OK, et al.

BMC medical informatics and decision making 2026; (26(1)).

Association Between Dipstick Hematuria and Elevated Albuminuria in a Hospital-Based Population with Diverse Chronic Conditions.

Tanintheerakul C, Peerakam R, Nanthawong P, et al.

Diagnostics (Basel, Switzerland) 2026; (16(11)) doi:10.3390/diagnostics16111678.

Hypertension in chronic kidney disease: where do international guidelines converge and diverge?

Stambolliu E, Stathopoulou E, Bora M, Damianaki A

Clinical hypertension 2026; (32()):e32 doi:10.5646/ch.2026.32.e32.

A Case Report of Isolated Hypertensive Choroidopathy in a Context of Renal Failure due to Suspected Prolonged High-Protein Diet Intake Combined with Anabolic Steroid Use.

Maris V, Barioulet L, Roubelat FP, et al.

Case reports in ophthalmology 2026; (17(1)):739-745 doi:10.1159/000552088.